Evaluation of β-blockers dosage regimen rationality in heart failure patients

Anna Sira Coulibaly; Shibi Mary Thomas; Prashant Kumar  Sah; Balakeshwa Ramaiah; Prestley F. Chia-Sani; Salimata  Kone

doi:10.18203/2319-2003.ijbcp20233197

Authors

Anna Sira Coulibaly Department of Pharmacy Practice, Karnataka College of Pharmacy, Bangalore, Karnataka, India
Shibi Mary Thomas Department of Pharmacy Practice, Karnataka College of Pharmacy, Bangalore, Karnataka, India
Prashant Kumar Sah Department of Pharmacy Practice, Karnataka College of Pharmacy, Bangalore, Karnataka, India
Balakeshwa Ramaiah Department of Pharmacy Practice, Karnataka College of Pharmacy, Bangalore, Karnataka, India
Prestley F. Chia-Sani Department of Pharmacy Practice, Karnataka College of Pharmacy, Bangalore, Karnataka, India
Salimata Kone Department of Public Health, Food and Agriculture (FAO), Bamako, Mali

DOI:

https://doi.org/10.18203/2319-2003.ijbcp20233197

Keywords:

Rationality, Guidelines, β Blockers, Effectiveness, Mortality

Abstract

Background: β-Blockers are often associated with further cardiac function deterioration, ledding to them being often underused/underdosed by certain physicians in heart failure treatment, although they were seen to be beneficial in decreasing the rates of mortality and morbidity, duration of hospitalization in HFrEF patients, but data on their benefits in HFmEF and HFpEF patients is limited. Objective was to evaluate rationality of β-blockers’ dosage regimen and its effectiveness in HF patients.

Methods: 43 HF patients have been enrolled. Data were collected from the medication chart (dose, route, frequency); dosage regimen was evaluated and compared to that of ESC guidelines for HF treatment. Heart rates pre/post drug treatments, ejection fraction (at admission & post-discharge) were recorded; effectiveness was evaluated through heart rate control, reduction in: duration of hospitalization, rehospitalization and mortality rate. Post-discharge updates of the patients were obtained through out-patient consultation reports.

Results: In All 43 patients dosage regimen of selected β-Blockers was found to be rational and following the ESC guideline for HF treatment. 65% of patients spent not more than 5 days in the hospital, 16% Re-hospitalized for cardiovascular diseases, and death rate was 4%.

Conclusions: The dosage regimen of selected β-Blockers was found to be as per that of ESC-guidelines HF treatment. β-Blockers have also been found to have reduced: hospitalization stay, frequency of rehospitalization, and death rate among patients under study.

Metrics

Metrics Loading ...

References

Daniele M, Maria L M, Vittoria E, Giuseppe P. The use of β-Blockers in heart failure with Reduced Ejection Fraction. J Cardiovasc Dev Dis. 2021;8(9): 101.

Denbow CE. Beta-adrenergic blockade in the treatment of congestive heart failure. West Indian Med J. 2000;49(2):102-7.

Abraham WT. Beta-blockers: the new standard of therapy for mild heart failure. Arch Intern Med. 2000;160(9):1237-47.

Squire IB, Barnett DB. The rational use of β-adrenoceptor blockers in the treatment of heart failure: The changing face of an old therapy. Br J Clin Pharmacol. 2000;49(1):1-9.

John GFC, Karina VB, Marcus DF, Douglas GAA, Jane H, Andrew JSC, et al. Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. Eurheartj. 2018; 39(1):26-35.

Daniele M, Maria L M, Vittoria E, Giuseppe P. The use of β-Blockers in heart failure with Reduced Ejection Fraction. J Cardiovasc Dev Dis. 2021;8(9): 101.

Theresa AM, Marco M, Marianna A, Roy SG, Andreas B, Michael B, et al. 2021 ESC Guidelines for the Diagnosis and treatment of acute and chronic Heart failure. Eurheart J. 2021;42(36):3599-726.

Michael L. Clinical toxicology of beta-blocker overdose in adults. Basic clin Pharmacol Toxicol. 2019;125(2):178-86.

Chaturvedi V P, Mathur A G, Anand A C. Rational drug use-As common as common sense?. Med J Armed forces India. 2012;68(3):206-8.

Piotr P, Adriaan AV, Stefan D, Héctor B, John GFC, Andrew JSC, et al. 2016 ESC Guidelines for the Diagnosis and treatment of acute and chronic heart failure: The Task Force for the Diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016; 37(27):2129-200.

Theresa AM, Marco M, Marianna A, Roy SG, Andreas B, Michael B, et al. 2021 ESC Guidelines for the Diagnosis and treatment of acute and chronic Heart failure. Eurheart J. 2021;42(36):3599-726.

Baoshan L, Rui Z, Aiyuan Z, Guodong W, Jiupan X, Yun Z, et al. Effectiveness and Safety of Four different beta-blockers in patients with chronic heart failure. Med Comm. 2023;4(1):23-9.

Stoschitzky K, Stoschitzky G, Brussee H, Bonelli C, Dobnig H. Comparing beta-blocking effects of bisoprolol, carvedilol and nebivolol. Cardiology 2006;106(4):199-206.

Stefania P, Simona D, Immacolata, Alessandra P, Pasquale P F. The use of β-blockers in patients with heart failure and comorbidities: Doubts, certainties and unsolved issues. Eur J Intern Med. 2021;88:9-14.

Pornwalee P, Pramote P, Henry. Is target dose of Beta-Blocker more important than Achieved Heart Rate or Heart rate change in Patients with Systolic Chronic Heart failure?. Cardiovascul Therap. 2010;28(2):93-100.

Dennis TK, Patricia RH, Christopher SC, Jeptha PC, JoAnne MF, Artyom S, et al. Adverse effects of beta-blocker therapy for patients with heart failure: a quantitative overview of randomized trials. Arch Intern Med. 2004;164(13):1389-94.

John GFC, Karina VB, Marcus DF, Douglas GA, Jane H, Andrew JSC, et al. Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. Eurheartj. 2018; 39(1):26-35.